Skip to main content
. 2022 Nov 29;66(12):e00564-22. doi: 10.1128/aac.00564-22

TABLE 3.

Determination of the interaction of GEPO with front-line antimycobacterial drugs against M. fortuitum ATCC 6841, M. abscessus ATCC 19977, and M. tuberculosis ATCC 27294

Strain and drugs MIC of drug alone (mg/L) MIC of drug in presence of gepotidacin (mg/L) MIC of gepotidacin alone (mg/L) MIC of gepotidacin in presence of drug (mg/L) FIC index Indication
M. fortuitum ATCC 6841
 Amikacin 0.5 0.25 1 0.125 0.62 No interaction
 Meropenem 1 0.25 1 0.06 0.31 Synergistic
 Moxifloxacin 0.06 0.0075 1 0.125 0.25 Synergistic
 Clarithromycin 1 0.5 1 0.25 0.75 No interaction
 Ciprofloxacin 0.06 0.015 1 0.125 0.37 Synergistic
 Linezolid 1 0.06 1 0.125 0.18 Synergistic
 Vancomycin 0.25 0.25 1 0.06 1.06 No interaction
M. abscessus ATCC 19977
 Amikacin 2 0.5 2 0.125 0.31 Synergistic
 Clarithromycin 0.5 0.5 2 1 1.5 No interaction
 Moxifloxacin 2 0.5 2 0.06 0.28 Synergistic
 Ciprofloxacin 1 0.125 2 0.125 0.18 Synergistic
M. tuberculosis ATCC 27294
 Isoniazid 0.03 0.0075 1 0.015 0.265 Synergistic
 Rifampicin 0.06 0.03 1 0.5 1 No interaction
 Ethambutol 1 0.5 1 0.5 1 No interaction
 Streptomycin 1 0.5 1 0.25 0.75 No interaction